Early Evidence of the Effect of SARS-CoV-2 Vaccine at One Medical Center
Item
Click for External Resource*
Click to read full article*
*The link above may share a zip file (.zip) hosted on repository.netecweb.org. Zip files will download automatically.
*All other links are external and will open in a new window. If you click an external link, you are leaving the NETEC site, and we do not maintain, review, or endorse these materials. See our terms of use.
Item Type
PublicationTerms of Use
By accessing these materials you are agreeing to our terms of use, which may be found here: Terms of Use.
Example only: NETEC provides this item for reference purposes but does not endorse its content. Newer versions may be in place at the providing institution.
Title
Early Evidence of the Effect of SARS-CoV-2 Vaccine at One Medical Center
Subject
Description
Emergency use authorizations for two messenger RNA (mRNA) vaccines — the BNT162b2 vaccine (Pfizer–BioNTech) and the mRNA-1273 vaccine (Moderna) — marked important milestones in efforts to respond to the coronavirus disease 2019 (Covid-19) pandemic. These Food and Drug Administration actions were based on impressive results of clinical trials, but only in the weeks since the authorizations has real-world evidence been available to shed light on the overall effect of the vaccines on transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and related illness.
Date
2021-05-20
Type
Citation
Daniel, William, Marc Nivet, John Warner, and Daniel K. Podolsky. 2021. "Early Evidence of the Effect of SARS-CoV-2 Vaccine at One Medical Center." New England Journal of Medicine 384 (20):1962-3.
Accessibility
Free online on NEJM.
Was this resource helpful?